GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan YZY Biopharma Co Ltd (HKSE:02496) » Definitions » Current Ratio

Wuhan YZY Biopharma Co (HKSE:02496) Current Ratio : 1.44 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Wuhan YZY Biopharma Co Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Wuhan YZY Biopharma Co's current ratio for the quarter that ended in Dec. 2023 was 1.44.

Wuhan YZY Biopharma Co has a current ratio of 1.44. It generally indicates good short-term financial strength.

The historical rank and industry rank for Wuhan YZY Biopharma Co's Current Ratio or its related term are showing as below:

HKSE:02496' s Current Ratio Range Over the Past 10 Years
Min: 1.44   Med: 1.63   Max: 2.21
Current: 1.44

During the past 3 years, Wuhan YZY Biopharma Co's highest Current Ratio was 2.21. The lowest was 1.44. And the median was 1.63.

HKSE:02496's Current Ratio is ranked worse than
75.86% of 1545 companies
in the Biotechnology industry
Industry Median: 3.79 vs HKSE:02496: 1.44

Wuhan YZY Biopharma Co Current Ratio Historical Data

The historical data trend for Wuhan YZY Biopharma Co's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan YZY Biopharma Co Current Ratio Chart

Wuhan YZY Biopharma Co Annual Data
Trend Dec21 Dec22 Dec23
Current Ratio
2.21 1.63 1.44

Wuhan YZY Biopharma Co Semi-Annual Data
Dec21 Dec22 Dec23
Current Ratio 2.21 1.63 1.44

Competitive Comparison of Wuhan YZY Biopharma Co's Current Ratio

For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan YZY Biopharma Co's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Current Ratio distribution charts can be found below:

* The bar in red indicates where Wuhan YZY Biopharma Co's Current Ratio falls into.



Wuhan YZY Biopharma Co Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Wuhan YZY Biopharma Co's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=273.555/190.121
=1.44

Wuhan YZY Biopharma Co's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=273.555/190.121
=1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan YZY Biopharma Co  (HKSE:02496) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Wuhan YZY Biopharma Co Current Ratio Related Terms

Thank you for viewing the detailed overview of Wuhan YZY Biopharma Co's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan YZY Biopharma Co (HKSE:02496) Business Description

Traded in Other Exchanges
N/A
Address
No. 666 Gaoxin Road, East Lake High Tech, Development Zone, Hubei Province, Wuhan, CHN
Wuhan YZY Biopharma Co Ltd is a biotechnology company specifically involved in developing bispecific antibody based therapies to treat cancer or cancer-associated complications, cancer and age-related ophthalmologic diseases to address medical demands in oncology and aging-related ophthalmologic disease areas, The Company has been operating in one reportable segment, being the discovering, developing and commercializing new class of innovative medicines in respect to anti-tumor bispecific antibody.
Executives
Dragon Merit Holdings Limited 2201 Interest of corporation controlled by you
Robust Sun Holdings Limited 2201 Interest of corporation controlled by you
Cspc Pharmaceutical Group Limited 2201 Interest of corporation controlled by you
Shi Yao Ji Tuan En Bi Pu Yao Ye You Xian Gong Si 2101 Beneficial owner
He Bei Yi Er Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Ning Bo Mei Shan Bao Shui Gang Qu Guang Rui Hong Xiang Gu Quan Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Guo Xin Si Chuang Tou Zi Ji Jin Guan Li Bei Jing You Xian Gong Si 2201 Interest of corporation controlled by you
Guo Hong Wei
Nan Jing Cai Zhi Er Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Nan Ning Hui You Xing Yao Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Nan Ning Yao You Shang Wu Zi Xun He Huo Qi Ye You Xian He Huo
Wen Zhi Cheng
Tong De Qian Yuan Bei Jing Tou Zi Guan Li You Xian Gong Si
Wang Hongjie 2201 Interest of corporation controlled by you
Wu Shangzhi 2201 Interest of corporation controlled by you

Wuhan YZY Biopharma Co (HKSE:02496) Headlines

No Headlines